BOSTON, Jan. 20, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company") announced today the addition of two new Scientific Advisory Board (SAB) members: Linda Giudice, MD, PhD, and Marianne Mann, MD.
"Dr. Linda Giudice and Dr. Marianne Mann bring vast knowledge and well-informed perspective to our Scientific Advisory Board," said Dr. Martyn Davies, Chairman of Juniper's Scientific Advisory Board. "Dr. Giudice is a leader in women's healthcare with extensive clinical experience, while Dr. Mann has wide-ranging regulatory expertise honed both during and since her tenure at the FDA. We look forward to their input as we support Juniper's management to advance and further expand the Company's pipeline of differentiated women's health products."
A widely-respected biochemist, gynecologist, and reproductive endocrinologist, Dr. Linda Giudice is the Robert B. Jaffe MD Endowed Professor and Chair of the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California, San Francisco (UCSF) School of Medicine. She is also Director of the UCSF Laboratory of Human Endometrial Biology, Functional Genomics, and Stem Cell Research
Dr. Giudice specializes in endometriosis, implantation and ovulatory disorders, infertility and assisted reproduction. Her research pursuits include endometrial biology and placental-uterine interactions as well as environmental impacts on reproductive health.
The author of over 250 publications, Dr. Giudice earned a Ph.D. in biochemistry at UCLA and a Medical Doctorate at Stanford University. She has served on numerous NIH study sections, is former Chair of the Reproductive Health Drugs Advisory Committee to the FDA, and chaired the NIH Reproductive Medicine Network and Specialized Cooperative Centers Program in Reproduction and Infertility Research Steering Committees. Dr. Giudice was elected to the Institute of Medicine (now the National Academy of Medicine) in 2002.
Dr. Marianne Mann is an independent pharmaceutical development and regulatory consultant with extensive experience in regulatory affairs. During her nine-year tenure at the FDA, Dr. Mann served as Deputy Director of two drug product divisions, Reproductive/Urologic and Pulmonary/Allergy, and as a Medical Officer in the Antiviral and Special Pathogen divisions. While at the FDA, Dr. Mann reviewed clinical protocols from the early phases of drug development through post-marketing for numerous therapeutic products.
Since leaving the FDA in 2003, Dr. Mann has consulted on multiple projects across dozens of therapeutic areas for products in various stages of development. She has served on many drug advisory and drug safety boards, has helped prepare sponsors for FDA advisory panels including serving on mock advisory panels, and in May 2013 presented findings of adjudicated anaphylaxis events for a testosterone product at an FDA panel meeting.
A pulmonologist and intensivist by training, Dr. Mann earned her Medical Doctorate at the Medical College of Pennsylvania in conjunction with Lehigh University in an accelerated six-year combined Bachelor's and Medical Doctorate program. She has authored numerous scientific publications and received multiple FDA awards including the FDA Award of Merit (1998), the Department of Health and Human Services Secretary's Award for Distinguished Service (1998), and the CDER Excellence in Communication Award (2002).
Juniper's SAB is comprised of internationally renowned physicians and scientists, whose mission is to provide scientific and clinical advice on the identification and advancement of product candidates for the Company's women's health portfolio. SAB members are Ginger D. Constantine, MD; William F. Crowley Jr., MD; Martyn Davies, BSc, Ph.D., FRPharmS, CChem, FRSC (Chair); Linda Giudice, MD, PhD, Robert S. Langer, Sc.D.; Marianne Mann, MD; and, Daniel A. Shames, MD, FACS, who will transition to an emeritus role upon his retirement later this spring.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. Juniper has a commercial product, CRINONE® 8% (progesterone gel), which is marketed by Allergan, Inc. in the U.S. and by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide. The Company is advancing a pipeline of proprietary drug candidates leveraging novel delivery technologies. Please visit www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Allergan, Inc. in the U.S. and of Merck KGaA, Darmstadt, Germany, outside the U.S.
Forward Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are usually indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," or similar expressions, and which are generally not historical in nature. These include all statements relating to expected benefits of Dr. Giudice's and Dr. Mann's contributions to Juniper's Scientific Advisory Board and future business or product developments. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law. For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2014.
Contact Amy Raskopf Director, Corporate Communications Juniper Pharmaceuticals (917) 673-5775 firstname.lastname@example.org
SOURCE Juniper Pharmaceuticals, Inc.